The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 05, 2019

Filed:

Aug. 25, 2016
Applicant:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Inventors:

Elke Faatz, Huglfing, DE;

Christian Scholz, Penzberg, DE;

Peter Muench, Penzberg, DE;

Assignee:

Roche Diagnostics Operations, Inc., Indianapolis, IN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); G01N 33/569 (2006.01); C07K 14/005 (2006.01);
U.S. Cl.
CPC ...
G01N 33/56988 (2013.01); C07K 14/005 (2013.01); G01N 33/56983 (2013.01); C07K 2319/35 (2013.01); C12N 2740/14022 (2013.01); C12N 2740/14031 (2013.01); C12N 2740/14051 (2013.01); G01N 2333/15 (2013.01); G01N 2469/20 (2013.01);
Abstract

The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.


Find Patent Forward Citations

Loading…